Article
U.S. FDA panel votes against Amylyx's ALS drug over trial data concerns
Rating:
0.0
Views:
25
Likes:
1
Library:
1
A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday voted against approving Amylyx Pharmaceuticals Inc's drug for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value